Serious Gram-negative (GN) pathogens are clinically-important patho-gens in both the hospital and outpatient settings. GN pathogens are often acquired in healthcare facilities, and therefore have a high incidence of drug resistance to even the most powerful of antibiotics (e.g. third-generation cephalosporins, fluoroquinolones, and carbapenems). Howev-er, there have only been three new agents approved in the last ten years. As a result, there is a high need for new therapies for multi-drug-resistant (MDR) GN pathogens.
This report provides insight into the management of patients with GN in-fections in the hospital setting and analyzes the hospital antibiotic pre-scribing practices for the treatment of key infections due to emerging and clinically-important Gram-negative pathogens. The study provides longitu-dinal information on market dynamics, including insight into practice pat-terns, attitudes and perceptions, unmet needs, and projected use of anti-biotics in the hospital setting. These studies also explore the perceived advantages and disadvantages of currently available therapies and thera-pies in development
Questions Answered in This Report:
How are physicians treating serious infections due to emerging and clinically-important pathogens?
Which pathogens are of concern to physicians, and which pose new treatment challenges and drug de-velopment opportunities?
How do physicians make treatment choices for GN infections, includ-ing empiric treatment for suspected GN infections and discharge ther-apies?
How are severe skin infections, blood stream infections, nosocomial pneumonia, intra-abdominal infections, and bone and joint infections treated?
What are physicians’ therapy preferences and what factors and drug attributes influence current and future prescribing patterns?
How re-ceptive are physicians to novel and emerging therapies?
100 infectious diseases specialists completed a 45-minute online quanti-tative survey with several open-ended questions for qualitative feedback.
To qualify, respondents met the following criteria:
Be board-certified in infectious diseases
Treated a minimum of 10 patients with MRSA within the last month
Have been in practice a minimum of 2 years and a maximum of 30 years
At east 50 percent of time practicing in the hospital setting
Key Drugs Covered:
Merrem (meropenem), Primaxin(imipenem/cilastatin), Doribax (doripenem), Invanz (ertapenem), Zosyn (piperacillin/tazobactam), Tygacil (tigecycline), Levaquin(levofloxacin), Avelox (moxifloxacin), other key generic competition, and agents in late-stage development including CXA-201, ceftobiprole, CAZ-AVI, and TP-434
Final report in PowerPoint format
Trending will be provided for clients purchasing relevant previous reports
Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request
Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions
Physician and Payer Forum®: Gram-Negative Infections (US)
Physician and Payer Forum®: Gram-Negative Infections (EU)
DecisionBase®: Hospital-Acquired Pneumonia
TreatmentTrends®: MRSA and Serious Gram-Positive Infections (EU)
PatientBase®: Hospital-Treated Infections in G7
Pharmacor®: Hospital-Treated Infections
Pharmacor®: Methicillin-Resistant Staphylococcus aureus
Hospital Formulary Insights®: Anti-Infectives (US)
Hospital Formulary Insights®: Antibiotics (EU)
TreatmentTrends®: Clostridium difficile Infections (EU)
TreatmentTrends®: Clostridium difficile Infections (US)